Improved cancer-specific free survival and overall free survival in contemporary metastatic prostate cancer patients


Over the past decade, several systemic agents as Docetaxel, Cabazitaxel, Sipuleucel-T, Abiraterone and Enzalutamide have improved overall survival ( OS ) in metastatic prostate cancer ( mPCa ) patients.
However, to date the overall survival benefit was not demonstrated in population-based analysis.

Between 2004 and 2014, 19,047 men with de novo metastatic prostate cancer were identified within the SEER ( Surveillance Epidemiology and End Results ) database.
Median year of diagnosis resulted in two groups: historical ( 2004–2008 ) and contemporary ( 2009–2014 ).

Due to potentially important differences according to year of diagnosis, researchers relied on propensity score matching.
Propensity-score-matched Kaplan–Meier analyses and Cox regression models ( CRMs ) tested cancer-specific mortality ( CSM ) free survival and overall mortality ( OM ) free survival according to treatment period.

The propensity-score-matched cohort consisted of 8596 patients with metastatic prostate cancer. Of those, 4298 ( 50.0% ) were historical ( 2004–2008 ) and 4298 ( 50.0% ) were contemporary ( 2009–2014 ).

Cancer-specific mortality free survival rates and overall mortality free survival rate were 32 versus 36 months ( p less than 0.0001 ) and 26 versus 29 months ( p less than 0.0001 ) for, respectively, historical and contemporary patients.

In multivariable CRMs, patients diagnosed in contemporary years had lower cancer-specific mortality ( hazard ratio, HR=0.88; CI 0.82–0.93 ) and overall mortality ( HR=0.88; CI 0.84–0.93 ) risks compared to historical counterpart ( all p less than 0.0001 ).

In conclusion, this population-based study provides the first evidence of improved cancer-specific mortality free survival and overall mortality free survival in patients with de novo metastatic prostate cancer since the introduction of several systemic agents for patients with castration-resistant prostate cancer ( CRPC ). ( Xagena )

Bandini, M., Pompe, R.S., Marchioni, M. et al. Int Urol Nephrol 2017

XagenaMedicine_2017



Indietro

Altri articoli

Lynparza ( Olaparib ) has been approved in the European Union ( EU ) for patients with metastatic castration-resistant prostate...


Cabozantinib ( Cabometyx ) may enhance response to immune checkpoint inhibitors ( ICIs ) by promoting an immune-permissive microenvironment and...


SPARTAN has evaluated Apalutamide ( Erleada ) versus placebo in patients with nonmetastatic castration-resistant prostate cancer ( nmCRPC ) and...


Tthe phase III IPATential150 study met its co-primary endpoint of radiographic progression-free survival ( rPFS ) in patients with metastatic...


Data, presented at 2018 American Society of Clinical Oncology ( ASCO ) Annual Meeting, showed clinical improvement in median radiologic...


ADXS-PSA, an attenuated Listeria monocytogenes-based immunotherapy that targets prostate-specific antigen ( PSA ), is designed to generate antigen-specific T cell...


Researchers have evaluated the use of Abiraterone acetate ( Zytiga ) ( 1,000 mg ) plus Prednisone ( 5 mg...


Data from the pivotal phase 3 LATITUDE clinical trial showed Abiraterone acetate ( Zytiga ) plus Prednisone, in combination with...


STAMPEDE is a multigroup, multistage platform trial protocol investigating the efficacy of additional therapy at the time of inception of...